News

Stocktwits on MSN1h

Retail Traders Pile Into Ionis As Wall Street Hikes Price Targets On FDA Approval Of Swelling Disorder Therapy

Wall Street analysts boosted their targets on Ionis Pharmaceuticals after the FDA approved its RNA-based drug Dawnzera for ...
Precision Medicine Online5h

Ionis Pharma's Dawnzera FDA Approved for Preventive Swelling Attacks of Rare, Genetic Condition

The antisense oligonucleotide is a prophylactic treatment for preventing swelling attacks due to hereditary angioedema.

Bageshri Banerjee

The latest international Bageshri Banerjee news and views from Reuters - one of the world's largest news agencies ...
BioWorld6h

Ionis gets approval for preventing attacks in rare and genetic HAE

In Ionis Pharmaceuticals Inc.’s second U.S. FDA approval in under a year, the agency approved Dawnzera (donidalorsen) as a prophylactic therapy in the rare and genetic disease hereditary angioedema ...
MedPage Today7h

RNA-Targeted Drug Approved for Preventing Hereditary Angioedema Attacks

In June, the monoclonal antibody garadacimab (Andembry) was approved for prevention of HAE attacks at a dose of once monthly ...
TipRanks on MSN9h

Ionis Pharmaceuticals price target raised to $64 from $63 at BofA

BofA analyst Jason Gerberry raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $64 from $63 and keeps a Buy rating on the shares ...
Fierce Pharma9h

Ionis steps into crowded HAE market with FDA approval for Dawnzera

Since 2008, the FDA has approved 11 treatments for a rare genetic condition called hereditary angioedema (HAE), three of ...

US FDA approves Ionis' drug for rare genetic disorder

(Reuters) -The U.S. Food and Drug Administration on Thursday approved Ionis Pharmaceuticals' drug to prevent instances of ...

Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder

On Thursday, the U.S. Food and Drug Administration (FDA) approved Ionis Pharmaceuticals, Inc.’s (NASDAQ:IONS) Dawnzera ...

Ionis Gets FDA OK of Dawnzera in Hereditary Angioedema

Ionis on Thursday said the FDA green light covers Dawnzera for prophylaxis to prevent attacks of hereditary angioedema in patients 12 years of age and older and makes the drug is the first and only ...
STAT12h

FDA approves Ionis drug that prevents swelling attacks caused by a rare disease

Ionis Pharmaceuticals won FDA approval for a drug that prevents painful swelling attacks triggered by a rare genetic ...

Ionis Halted as FDA Decision Looms on Hereditary Angioedema Drug

Trading in shares of Ionis Pharmaceuticals is halted Thursday ahead of an expected decision from the U.S. Food and Drug Administration on the company's proposed donidalorsen treatment for hereditary ...